Currently, the second- and third-generation TKIs afatinib and osimertinib, which irreversibly bind to the kinase domain of the EGFR, have become the leading choice of treatment for lung cancer harboring EGFR mutations [7,8,9]. This evidence concerns the gene EGFR and lung carcinoma.